KORU Medical Systems (KRMD) director awarded 3,571 Common Stock shares

Rhea-AI Filing Summary

KORU Medical Systems director Edward Wholihan received a grant of 3,571 shares of Common Stock, valued at $4.20 per share. This is a compensation-related award reported as an acquisition, not an open-market purchase. After the grant, his direct ownership totals 51,312 shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider WHOLIHAN EDWARD

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	3,571	$4.20	$15K

Holdings After Transaction: Common Stock — 51,312 shares (Direct, null)

Footnotes (1)

Key Figures

Share grant: 3,571 shares Grant price: $4.20 per share Post-transaction holdings: 51,312 shares

3 metrics

Share grant 3,571 shares Common Stock grant reported on Form 4

Grant price $4.20 per share Transaction price per share for the award

Post-transaction holdings 51,312 shares Direct Common Stock ownership after grant

Key Terms

Form 4, Common Stock, Grant, award, or other acquisition

3 terms

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Common Stock financial

" "security_title": "Common Stock","

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Grant, award, or other acquisition financial

""transaction_code_description": "Grant, award, or other acquisition""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/01/2026 - 05:21 PM Accepted by SEC EDGAR 07/01/2026 - 05:21 PM Learn about SEC filing dates

FAQ

What insider transaction did KRMD director Edward Wholihan report?

Director Edward Wholihan reported receiving a grant of 3,571 KRMD Common Stock shares. The award was recorded at $4.20 per share and is classified as a grant or other acquisition, rather than an open-market purchase or sale.

Was the KRMD Form 4 transaction a buy or a sale of shares?

The KRMD Form 4 transaction was neither a buy nor a sale. It was reported under code A as a grant or award acquisition of 3,571 Common Stock shares, reflecting a compensation-related award instead of a market trade.

How many KRMD shares does Edward Wholihan hold after this grant?

After the reported grant, Edward Wholihan directly holds 51,312 shares of KRMD Common Stock. This total includes the newly granted 3,571 shares and represents his direct ownership position following the compensation-related transaction.

What price was used for the KRMD share grant to Edward Wholihan?

The KRMD share grant to Edward Wholihan used a price of $4.20 per share. This price is shown in the Form 4 as the transaction price per share for the 3,571 Common Stock shares acquired through the compensation-related award.

Does the KRMD Form 4 show any derivative or option exercises?

The KRMD Form 4 does not show any derivative or option exercises. It reports only a non-derivative transaction: a grant or award of 3,571 Common Stock shares, with no remaining derivative positions listed in the derivative summary section.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WHOLIHAN EDWARD

(Last) (First) (Middle)

C/O KORU MEDICAL SYSTEMS, INC.

100 CORPORATE DRIVE

(Street)

MAHWAH NEW JERSEY 07430

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
KORU Medical Systems, Inc. [ KRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/01/2026		A		3,571	A	$4.2	51,312	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

The filing of this statement shall not be construed as an admission (a) that the person filing this statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this statement, or (b) that this statement is legally required to be filed by such person. Power of Attorney has been previously filed.

	/s/ Thomas Adams - Attorney-in-Fact	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)